Both receptors, as well as peroxisome proliferator-activated receptors (PPARs), impact lipid metabolism and apparently participate in NAFLD development and its progression to NASH.11,12 Specifically, CB1 (and to a lesser extent CB2) antagonism is a strategy to prevent or reduce hepatic steatosis in pre-clinical models.11 This evidence concerns the gene CNR1 and Hepatic steatosis.